Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
Journal of Hematology & Oncology, 07/06/2012
Huang X et al. – Men with metastatic castration–resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel–based regimens which has modest survival benefit shown by randomized clinical trials. Significant progress in the discovery of novel therapeutic agents has been made in the past few years. While sipuleucel–T, cabazitaxel, and abiraterone gained regulatory approval in 2010 and 2011, several highly promising candidates/regimen have failed in large scale clinical trials. Challenges remain to optimize the design and interpretation of clinical trial results and develop more effective strategies for mCRPC.